Results 21 to 30 of about 2,758 (199)

Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary [PDF]

Journal of Comparative Effectiveness Research
What is this summary about? Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease where red blood cells break apart because they lack certain protective proteins.
Celso Arrais, Natalia Carnelutto, Jheremy Reyes   +2 more
doaj   +2 more sources

Disease Activity After Switching From Eculizumab to Ravulizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria: Real World Data From Denmark and Finland [PDF]

eJHaem
Introduction Ravulizumab replaced eculizumab as the preferred complement inhibitor for Paroxysmal Nocturnal Haemoglobinuria (PNH) in Denmark and Finland after 2020. Data on real‐world disease activity after switching are limited.
Anders Rønneholt‐Frederiksen, Dennis Lund Hansen, Vuokko Nummi, Jesper Stentoft, Ulrik M. Overgaard, Rie Sander Bech, Anna‐Elina Lehtinen, Andreas Glenthøj, Henrik Frederiksen   +8 more
doaj   +2 more sources

Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry. [PDF]

Am J Hematol
ABSTRACT Ravulizumab, a second‐generation complement component 5 inhibitor (C5i) derived from eculizumab, with improved pharmacokinetics, is the current standard‐of‐care treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), where available.
Röth A, Patriquin CJ, Szer J, Terriou L, Patel AS, Metzger J, Gustovic P, Nishimura JI, Brodsky RA.   +8 more
europepmc   +2 more sources

Complement Inhibition Therapy in Myasthenic Crisis-A Multicentre Retrospective Analysis of 17 Cases From Germany. [PDF]

Eur J Neurol
C5‐inhibition may represent an effective adjunctive treatment in therapy‐refractory myasthenic crisis, including thymoma‐associated MG (TAMG). ABSTRACT Introduction Generalized myasthenia gravis (gMG) may progress to life‐threatening myasthenic crises (MC) requiring mechanical ventilation.
Gerischer L, Stein M, Schneider A, Tangen H, Loris J, Glaubitz S, Zschüntzsch J, Oy UH, Schubert C, Heesen C, Schlag M, Hagenacker T, Oeztuerk M, Ruck T, Doksani P, Dusemund C, Herdick M, Herzig-Nichtweiß J, Mergenthaler P, Stascheit F, Suboh A, Schwarz L, Hoffmann S, Meisel A, Lehnerer S.   +24 more
europepmc   +2 more sources

Successful management of unstable angina in a ravulizumab-treated patient with paroxysmal nocturnal hemoglobinuria [PDF]

, 2022
Ravulizumab is an anti-C5 antibody approved for treating paroxysmal nocturnal hemoglobinuria (PNH). In August 2019, a 77-year-old Japanese man with PNH, who had been on ravulizumab treatment for 2 years, was hospitalized for chest discomfort and malaise.
Fukatsu, Masahiko, Harada, Kayo, Ikezoe, Takayuki, Kimura, Satoshi, Mori, Hirotaka, Ohkawara, Hiroshi, Oikawa, Masayoshi, Sano, Takahiro, Shichishima, Tsutomu, Takahashi, Hiroshi, Takeishi, Yasuchika, 七島, 勉, 佐野, 隆浩, 原田, 佳代, 及川, 雅啓, 大河原, 浩, 木村, 哲, 森, 博隆, 池添, 隆之, 深津, 真彦, 竹石, 恭知, 高橋, 裕志   +21 more
core   +1 more source

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults [PDF]

, 2021
Hemolytic uremic syndrome; Kidney failure; RavulizumabSíndrome hemolítico urémico; Insuficiencia renal; RavulizumabSíndrome hemolític urèmic; Insuficiència renal; RavulizumabIntroduction Atypical hemolytic uremic syndrome (aHUS) is a rare, complex ...
Ariceta Iraola, Gema, Barbour, Thomas, Cataland, Spero, Garlo, Katherine, Heyne, Nils, Scully, Marie   +5 more
core   +1 more source

The potential of individualized dosing of ravulizumab to improve patient-friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs [PDF]

, 2021
Contains fulltext : 237767.pdf (Publisher’s version ) (Open Access)Ravulizumab is a very expensive complement C5-inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria, with a fixed-dosing interval of 8 weeks.
Avest, M. ter, Blijlevens, N.M.A., Burger, D.M., Heine, R. ter, Kar, N.C.A.J. van de, Kievit, W., Langemeijer, S.M.C., Schols, S.E.M.   +7 more
core   +1 more source

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Neurology and Therapy, 2023
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare ...
Tuan Vu, Andreas Meisel, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Rasha Aguzzi, Ahmed Enayetallah, Kathleen N. Beasley, Nishi Rampal, James F. Howard   +9 more
doaj   +1 more source

Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United StatesPlain language summary

Kidney Medicine, 2023
Rationale and Objective: Ravulizumab and eculizumab have shown efficacy for the treatment of atypical hemolytic uremic syndrome (aHUS), but real-world evidence for ravulizumab is limited owing to its more recent approval.
Yan Wang, Imad Al-Dakkak, Katherine Garlo, Moh-Lim Ong, Ioannis Tomazos, Arash Mahajerin   +5 more
doaj   +1 more source

Population PK-PD Modeling of Danicopan Add-On Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab or Eculizumab. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Danicopan is a first‐in‐class orally administered complement factor D inhibitor, approved as an add‐on therapy to ravulizumab or eculizumab for the treatment of clinically significant extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Chen J, Yang F, Li H, Pradhan R, Ortiz S.   +4 more
europepmc   +2 more sources